Cardiac and systemic haemodynamic complications of liver cirrhosis

Scandinavian Cardiovascular Journal

Volumn 43, Issue 4, 2009, Pages 218-225

  Henriksen, Jens H ^a   Møller, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autonomic dysfunction; Central hypovolaemia; Cirrhotic cardiomyopathy; Hyperdynamic systemic circulation; Vascular hyporeactivity

Indexed keywords

CARDIOMYOPATHY; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; CIRCULATION; HEART ARRHYTHMIA; HEMODYNAMICS; HOMEOSTASIS; PATHOPHYSIOLOGY; VASCULAR RESISTANCE;

ANIMALS; ARRHYTHMIAS, CARDIAC; BLOOD CIRCULATION; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; HEART FAILURE; HEMODYNAMICS; HOMEOSTASIS; HUMANS; LIVER CIRRHOSIS; VASCULAR RESISTANCE; VASODILATION;

EID: 70349561463     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430802691528     Document Type: Review

References (62)

1. Jepsen P, Vilstrup H, Andersen PK, Lash TL, Sørensen HT. Comorbidity and survival of Danish cirrhosis patients: A nationwide population-based cohort study. Hepatology. 2008;/ 48:/214-20.
2. Henriksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol. 2001;/34:/ 53-60.
3. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del- Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;/341:/ 403-409
4. Keiding S, Sørensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology. 2006;/43:/42-50.
5. La Villa G, Gentilini P. Hemodynamic alterations in liver cirrhosis. Mol Aspects Med. 2008;/29:/112-8.
6. Cárdenas A, Ginès P. Predicting mortality in cirrhosis. Serum sodium helps. N Engl J Med. 2008;/359:/1060-2.
7. Henriksen JH, Bendtsen F, Møller S. Normal red cell cardiac output in the hyperkinetic syndrome of alcoholic cirrhosis. J Hepatol. 2001;/34:/782-3.
8. Kowalski HJ, Abelmann WH. The cardiac output in Laennec's cirrhosis. J Clin Invest. 1953;/32:/1025-33.
9. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;/8:/1151-7.
10. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005. p. 139-155
11. Møller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-28..
12. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;/57:/268-78.
13. Caraceni P, Dazzani F, Salizzoni E, Domenicali M, Zambruni A, Trevisani F, et al. Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. Hepatology. 2008;/48:/559-66.
14. Møller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: Relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol. 2003;/ 284:/G970-9.
15. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology. 1995;/109:/1917-25.
16. Colombato LA, Albillos A, Groszmann RJ. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology. 1996;/110:/193- 8.
17. Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to lowadrenaline and elevated circulating calcitonin gene-related peptide but not to activated vasoconstrictor systems. Gut. 2001;/49:/112-8.
18. Andreu V, Perello A, Moitinho E, Escorseli A, Garcia-Pagán JC, Bosch J, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol. 2002;/36:/356-61.
19. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2001;/280:/G584-94.
20. Wang YX, Fitch RM. Vascular stiffness: Measurements, mechanisms and implications. Curr Vasc Pharmacol. 2004;/ 2:/379-84.
21. Balmain S, Padmanabhan N, Ferrell WR, Morton JJ, McMurray JJ. Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. Eur J Heart Fail. 2007;/9:/865-71.
22. Shapiro BP, Lam CS, Patel JB, Mohammed SF, Kruger M, Meyer DM, et al. Acute and chronic ventricular-arterial coupling in systole and diastole: Insights from an elderly hypertensive model. Hypertension. 2007;/50:/503-11.
23. Hansen TW, Jeppesen P, Torp-Pedersen C. Prognostic significance of aortic pulse-wave velocity. In: Yim PJ, editor. Vascular hemodynamics. Bioengineering and clinical perspectives. Hoboken, New Jersey: Wiley-Blackwell; 2008. p. 85-94.
24. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin- aldosterone system. JRAAS. 2004;/5:/102-8.
25. Møller S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol. 2006;/41:/4518.
26. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;/46:/935-46.
27. Møller S, Wiinberg N, Henriksen J H. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology. 1995;/22:/88-95.
28. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreceptor reflex sensitivity in alcoholic cirrhosis. Relations to haemodynamic and humoral systems. Am J Physiol. 2007;/ 292:/H2966-72.
29. Wiest R, Groszmann R J. The paradox of nitric oxide in cirrhsois and portal hypertension: Too much, not enough. Hepatology. 2002;/35:/478-91.
30. Iwakiri Y, Groszmann R J. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology. 2006;/43:/121-31.
31. Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: A hypothesis. Gut. 2005;/54:/1668-71.
32. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology. 2006;/130:/838-54.
33. Schrier R W. Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone. Am J Med. 2006;/119:/1917-25.
34. Wiest R, Jurzik L, Herold T, Straub RH, Schölmerich J. Role of NPY for vasoregulation in the splanchnic circulation during portal hypertension. Peptides. 2007;/28:/396-404.
35. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann R J. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;/290:/G980-7.
36. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;/46:/935-46.
37. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut. 2007;/56:/1310-8.
38. Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut. 2003;/52:/410-5.
39. Langer DA, Shah V H. Nitric oxide and portal hypertension: Interface of vasoreactivity and angiogenesis. J Hepatol. 2006;/ 44:/209-16.
40. Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby D E. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut. 2005;/55:/542-6.
41. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;/43:/98-103.
42. Bolognesi M, Sacerdoti D, Di Pascoli M, Angeli P, Quarta S, Sticca A, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut. 2005;/54:/1630-6.
43. Hendrickse MT, Triger D R. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol. 1994;/89:/750-7.
44. Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen J H. Diurnal variation and dispersion in Q-T interval in cirrhosis. Relation to haemodynamic changes. J Hepatol. 2007;/47:/373-80.
45. Møller S, Henriksen J H. Cardiovascular dysfunction in cirrhosis. Patophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol. 2001;/36:/785-94.
46. Ma Z, Lee S S. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology. 1996;/24:/451-9.
47. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;/56:/869-75.
48. Møller S, Henriksen J H. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart. 2002;/87:/9-15.
49. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen J H. Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology. 1995;/22:/472-8.
50. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;/ 22:/326-32.
51. Pacher P, Batkai S, Kunos G. Cirrhotic cardiomyopathy:an endocannabinoid connection? Br J Pharmacol. 2005;/146:/ 313-314
52. Myers RP, Lee S S. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;/6:/44-52.
53. Krag A, Bendtsen F, Henriksen JH, Møller S. Cardiac effects of terlipressin in cirrhosis. Unmasking a cirrhotic cardiomyopathy. J Hepatol. 2007;/46:/96
54. Mohamed R, Forsey PR, Davies MK, Neuberger J M. Effect of liver transplantation on Q-T interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;/23:/1128-34.
55. Liu H, Gaskari S, Lee S S. Cardiac and vascular changes in cirrhosis: Pathogenic mechanisms. World J Gastroenterol. 2006;/12:/837-42.
56. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002;/36:/513-20.
57. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;/44:/994-1002.
58. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute nonselective -adrenergic blockade reduces prolonged frequencyadjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol. 2004;/40:/239-46.
59. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;/48:/415-21.
60. Bernardi M, Calandra S, Colantoni S, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepotology. 1998;/ 27:/28-34.
61. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;/52:/1511-7.
62. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac index predicts survival and renal failure in patients with ascites. Evidence of a heart-kidney axis in cirrhosis. J Hepatol. 2008;/48(Suppl 2):/s118.